Onterris (ONT) Q1 2026 earnings review
Transitory Headwinds Dent Q1, But Full-Year Confidence Intact
A rough start to 2026 for the newly rebranded Onterris. First-quarter revenue reversed course, dropping 5.2% YoY to $168.5 million. The contraction was driven by a $5.8 million drop in emergency response contracts and a $5.1 million hit from severe winter weather that idled field teams. This top-line squeeze pulled Adjusted EBITDA down 6% to $17.8 million. Operating cash flow also plunged into negative territory due to massive bonus payouts tied to 2025's record performance. However, management isn't blinking—they reaffirmed full-year guidance calling for ~10% EBITDA growth, signaling they view Q1 as a brief, weather-related stumble rather than a structural crack.
🐂 Bull Case
Despite lower overall sales, the newly formed Consulting & Treatment segment grew Adjusted EBITDA by 22% YoY, driving its margin from 13.9% to 17.5%. The underlying operational discipline is intact.
Management reaffirmed 2026 full-year guidance and expects Q2 revenue to jump back to roughly $200 million at the midpoint, proving the Q1 weather delays are purely timing-related.
🐻 Bear Case
The Measurement & Analysis segment saw revenue drop $5.1M, which immediately crushed segment EBITDA by 28%. The rapid margin compression (23.3% down to 18.4%) highlights high fixed costs during field delays.
Free cash flow was deeply negative at $(17.2) million. While driven by one-time 2025 outperformance bonuses, it drains liquidity at a time when the company wants to restart M&A.
⚖️ Verdict: ⚪
Neutral. The Q1 revenue and cash flow metrics look ugly on the surface, but the detailed breakdown supports management's claim that the issues are transitory. Still, execution risk for the remaining three quarters is now elevated as the company plays catch-up.
Key Themes
Consulting & Treatment Drives Margin Expansion
Following the segment realignment (merging Assessment, Permitting & Response with Remediation & Reuse), the new Consulting & Treatment division delivered a standout margin performance. Despite a revenue decline from $118.8M to $114.6M (due to lower emergency response), segment Adjusted EBITDA actually grew from $16.5M to $20.1M. This accelerating margin trend (13.9% to 17.5%) proves that management's cost discipline and project mix optimization are working effectively.
Weather Derails Measurement & Analysis
The Measurement & Analysis segment was the primary drag on Q1. Severe winter weather in North America restricted field teams and delayed lab deliveries. Revenue decelerated by $5.1M (down 8.6% YoY). Because this segment relies heavily on operating leverage, the revenue miss hit the bottom line hard: segment EBITDA fell 28% to $9.9M, and margins compressed drastically from 23.3% to 18.4%. Management views this as a timing issue, but it highlights the segment's vulnerability to external physical disruptions.
Bonus Payouts Crush Operating Cash Flow
Operating Cash Flow reversed violently, swinging from +$5.5M in 25Q1 to -$11.6M in 26Q1. The $17.1M deterioration was almost entirely driven by a $16.0M increase in bonus payments awarded for the company's record-breaking 2025 financial outperformance. While paying for performance is standard, a $(17.2)M Free Cash Flow print limits near-term capital flexibility.
Emergency Response Comps Create Growth Headwinds
Emergency response revenue remains a highly volatile, structural hurdle for year-over-year comparisons. In 26Q1, emergency revenue dropped to $8.1M (down from $13.9M in 25Q1). Investors must brace for an even larger hurdle in Q2: the company recorded a massive $48.5M in emergency response revenue in 25Q2, meaning total reported revenue in 26Q2 is almost guaranteed to show a steep YoY decline even if the core business thrives.
Rebranding to Onterris
On April 17, 2026, Montrose Environmental officially rebranded to Onterris, Inc. Management stated the move is designed to unify their platform, strengthen cross-selling, and align capabilities. Alongside the name change, consolidating reportable segments indicates a push to streamline the organizational structure and break down internal silos.
Other KPIs
Despite the drop in revenue and Adjusted EBITDA, Net Loss actually improved from $(19.4)M in 25Q1 to $(12.7)M. This reversal was driven by the elimination of the Series A-2 dividend (retired in mid-2025), a $4.7M decrease in stock-based compensation, and gains on hedging instruments.
Stable. Up slightly from 2.5x at the end of 2025, but well within management's comfort zone of operating below 3.0x. Total available liquidity sits at a healthy $188.4M ($10.0M cash + $178.4M revolver), providing ample runway for the planned resumption of M&A activity.
Guidance
Reversing. At the $200M midpoint, this represents a healthy ~19% sequential acceleration from Q1. However, due to the massive $48.5M emergency response event in 25Q2 (where total revenue hit $234.5M), this guidance implies a ~15% year-over-year decline. The core organic engine will need to perform exceptionally well to mask this comp.
Stable. The 17% midpoint is essentially flat compared to the 16.9% margin achieved in the record-breaking 25Q2, signaling that the structural margin improvements (particularly in Consulting & Treatment) are highly durable even without the benefit of massive emergency response leverage.
Stable. Reaffirmed from prior guidance. The midpoint of $870M represents roughly 5% total growth over 2025's $830.5M, but management specifies this includes ~8% organic growth. The outlook explicitly bakes in an expectation of $50M to $70M from emergency response work for the year.
Stable. Reaffirmed. The midpoint of $127.5M represents nearly 10% growth over 2025's $116.2M. Management expects full-year EBITDA margin to land at approximately 15%, implying a 100 basis-point expansion compared to 2025. Given the Q1 miss, achieving this requires flawless execution in H2.
Key Questions
Weather Delay Recapture
You noted that severe winter weather deferred $5.1M in Measurement & Analysis revenue. Is that revenue permanently lost, or is there a concrete backlog that will be fully recaptured in Q2 and Q3?
M&A Restart Parameters
You plan to restart bolt-on acquisitions in 2026. Given the negative free cash flow in Q1 and the desire to maintain leverage below 3.0x, what is the maximum capital outlay you are modeling for M&A this year?
Consulting & Treatment Margin Sustainability
The new Consulting & Treatment segment saw margins leap from 13.9% to 17.5% YoY despite lower revenues. How much of this 360 bps improvement is structural cost-cutting versus a temporary favorable mix of high-margin legacy projects?